AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14975486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 369
Study 14975486 — intervention group
Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 369
Study 11106873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg mCPP (low dose)
Number of subjects: 12
Study 11106873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg mCPP (standard dose)
Number of subjects: 12
Study 11106873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9596311 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 U of bleomycin sclerotherapy
Number of subjects: 106
Study 9596311 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of doxycycline sclerotherapy
Number of subjects: 106
Study 7843980 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages of change for dietary fat intake
Number of subjects: 17121
Study 7843980 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages of change for dietary fiber intake
Number of subjects: 17121
Study 7843980 — intervention group
Group type: COMPARATOR
Intervention: Demographic characteristics
Number of subjects: 17121
Study 3211079 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60
Study 3211079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiopentone
Number of subjects: 60
Study 30646122 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidated NICE rule (predictive algorithm for delirium)
Number of subjects: 39377
Study 30646122 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidated NICE rule
Number of subjects: 39377
Study 30646122 — intervention group
Group type: COMPARATOR
Intervention: eNICE rule
Number of subjects: 39377
Study 30646122 — intervention group
Group type: COMPARATOR
Intervention: Pendlebury NICE rule
Number of subjects: 39377
Study 27483320 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fat mass index
Number of subjects: 303
Study 27483320 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fat-free mass index
Number of subjects: 303
Study 24928284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pikasol® (3 capsules per day, 1.8 g EPA + DHA)
Number of subjects: 1400
Study 24928284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 1400
Study 23741829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lincomycin hydrochloride 500 mg capsules
Number of subjects: 41
Study 23741829 — intervention group
Group type: COMPARATOR
Intervention: Cefpodoxime proxetil 200 mg tablets
Number of subjects: 41
Study 20979799 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tiotropium 18 µg once daily
Number of subjects: 205
Study 20979799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 18757956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-bearing total knee replacement
Number of subjects: 242
Study 18757956 — intervention group
Group type: COMPARATOR
Intervention: Mobile-bearing total knee replacement
Number of subjects: 242
Study 16358136 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure (PEEP) associated with physiotherapy intervention (GEP)
Number of subjects: 24
Study 16358136 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy intervention alone (GPI)
Number of subjects: 24
Study 12461499 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (EPI)
Number of subjects: 149
Study 12461499 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (ALB)
Number of subjects: 149
Study 12461499 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (PLAC)
Number of subjects: 149
Study 10361658 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cigarette smoking
Number of subjects: 3222
Study 10361658 — intervention group
Group type: COMPARATOR
Intervention: No smoking (control group)
Number of subjects: 3222
Study 8775626 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated group (n = 12)
Number of subjects: 48
Study 8775626 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoperated group (n = 8)
Number of subjects: 48
Study 8775626 — intervention group
Group type: COMPARATOR
Intervention: Reference group (n = 46)
Number of subjects: 48
Study 8775626 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated group (n = 26)
Number of subjects: 48
Study 8775626 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoperated group (n = 22)
Number of subjects: 48
Study 2343912 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week treatment conditions (specifics not provided)
Number of subjects: 239
Study 7003855 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) lotion, applied daily for seven days, then weekly for seven weeks
Number of subjects: 187
Study 7003855 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 187
Study 7003855 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) lotion
Number of subjects: 187
Study 31544378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion therapy of Tiaochongren Gushenyuan
Number of subjects: 80
Study 31544378 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture and moxibustion (control group)
Number of subjects: 80
Study 29037576 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vaccination during pregnancy (not specified dosage or duration)
Number of subjects: 291
Study 26902229 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded capnography alarm
Number of subjects: 452
Study 26902229 — intervention group
Group type: COMPARATOR
Intervention: Open capnography alarm
Number of subjects: 452
Study 23379385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusive thoughts about cancer
Number of subjects: 558
Study 22825036 — intervention group
Group type: EXPERIMENTAL
Intervention: I-131 therapy (less than 11.1 GBq)
Number of subjects: 98
Study 22825036 — intervention group
Group type: EXPERIMENTAL
Intervention: I-131 therapy (11.1 GBq or more)
Number of subjects: 98
Study 22825036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no I-131 therapy)
Number of subjects: 98
Study 20413078 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Risk Behavior Surveillance System (YRBSS)
Number of subjects: 677
Study 20413078 — intervention group
Group type: EXPERIMENTAL
Intervention: YRBSS problem behaviors (conduct problems, sexual behavior, suicide/hopelessness)
Number of subjects: 677
Study 20413078 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic analysis of YRBSS subdomain scaling
Number of subjects: 677
Study 18285589 — intervention group
Group type: COMPARATOR
Intervention: Annual mass azithromycin administration
Number of subjects: 16803
Study 18285589 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual mass azithromycin administration
Number of subjects: 16803
Study 16355608 — intervention group
Group type: EXPERIMENTAL
Intervention: Changji' an (CJA) oral liquid
Number of subjects: 24
Study 16355608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 24
Study 12804182 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG treatment for GVHD prophylaxis
Number of subjects: 38
Study 12804182 — intervention group
Group type: COMPARATOR
Intervention: No ATG treatment for GVHD prophylaxis
Number of subjects: 38
Study 10588209 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg bolus of recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 606
Study 10588209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 10588209 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue and primary PTCA
Number of subjects: 606
Study 10588209 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 606
Study 10588209 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty after rt-PA
Number of subjects: 606
Study 10588209 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA and placebo
Number of subjects: 606
Study 9110470 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve conduction study in lead workers
Number of subjects: 20
Study 9110470 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomized)
Number of subjects: 20
Study 8475268 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic injection protocol
Number of subjects: 105
Study 8475268 — intervention group
Group type: COMPARATOR
Intervention: Uniphasic injection protocol
Number of subjects: 105
Study 3515926 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral flurbiprofen
Number of subjects: 92
Study 3515926 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of intramuscular morphine sulfate
Number of subjects: 92
Study 3515926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 31564356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection on a monthly basis for 3 months, followed by bimonthly injections for another 9 months.
Number of subjects: 36
Study 31564356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection
Number of subjects: 36
Study 31047350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg or 0.5 mg)
Number of subjects: 759
Study 31047350 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 759
Study 27681009 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First
Number of subjects: 156
Study 27681009 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 156
Study 24777811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 63
Study 24777811 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 63
Study 24777811 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/ezetimibe 10 mg
Number of subjects: 63
Study 24777811 — intervention group
Group type: COMPARATOR
Intervention: Control (Atorvastatin 10 mg during run-in period)
Number of subjects: 63
Study 24659566 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg/day for 12 weeks
Number of subjects: 66
Study 24659566 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg/day for 24 weeks
Number of subjects: 66
Study 24659566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clarithromycin)
Number of subjects: 66
Study 24659566 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin groups (both 12 and 24 weeks)
Number of subjects: 66
Study 23003211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral table tilt
Number of subjects: 35
Study 23003211 — intervention group
Group type: COMPARATOR
Intervention: Pelvic wedge
Number of subjects: 35
Study 18622878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen foam treatment (n = 98)
Number of subjects: 185
Study 18622878 — intervention group
Group type: COMPARATOR
Intervention: Local best practice (n = 87)
Number of subjects: 185
Study 17908130 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention with treatment fidelity procedures (specific details on dosage and duration not available)
Number of subjects: 0
Study 17908130 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment fidelity procedures applied in the SPHERE study
Number of subjects: 0
Study 17908130 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Consortium's model of treatment fidelity
Number of subjects: 0
Study 14684407 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral doses of 100 mg elemental Fe and 500 micro g folic acid
Number of subjects: 100
Study 14684407 — intervention group
Group type: COMPARATOR
Intervention: 3 intramuscular doses of 250 mg elemental Fe as iron dextran at 1‐mo intervals and oral doses of 5 mg folic acid twice weekly
Number of subjects: 100
Study 11748974 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 93
Study 11748974 — intervention group
Group type: COMPARATOR
Intervention: No fibrin glue (Control)
Number of subjects: 93
Study 9658755 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-mounted accelerometer
Number of subjects: 0
Study 9658755 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait analysis
Number of subjects: 0
Study 9658755 — intervention group
Group type: COMPARATOR
Intervention: Ankle fixation
Number of subjects: 0
Study 9658755 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation using a rigid-body model
Number of subjects: 0
Study 8677931 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 4 weeks plus amoxycillin 3 g daily and metronidazole 1 g daily during the 2nd and 3rd week (group A)
Number of subjects: 183
Study 8677931 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (group B)
Number of subjects: 183
Study 1761941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheehy collar button ventilation tube
Number of subjects: 0
Study 1761941 — intervention group
Group type: COMPARATOR
Intervention: Shepard tube
Number of subjects: 0
Study 6121479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atenolol (5 mg) followed by oral atenolol (50 mg)
Number of subjects: 203
Study 6121479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atenolol (5 to 15 mg)
Number of subjects: 203
Study 6121479 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 203
Study 6121479 — intervention group
Group type: COMPARATOR
Intervention: No beta blockade
Number of subjects: 203
Study 31191106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 13
Study 31191106 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 13
Study 31191106 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal Isometric Muscle Activity (SIMA)
Number of subjects: 13
Study 31191106 — intervention group
Group type: COMPARATOR
Intervention: Control Condition
Number of subjects: 13
Study 28065557 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual laryngeal fixation (MLF) with Macintosh laryngoscope (McL)
Number of subjects: 31
Study 28065557 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual laryngeal fixation (MLF) with McGRATH® MAC (McGRGTH)
Number of subjects: 31
Study 28065557 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual laryngeal fixation (MLF) with Pentax‐AWS Airwayscope® (AWS)
Number of subjects: 31
Study 28065557 — intervention group
Group type: COMPARATOR
Intervention: Without manual laryngeal fixation (MLF) with Macintosh laryngoscope (McL)
Number of subjects: 31
Study 28065557 — intervention group
Group type: COMPARATOR
Intervention: Without manual laryngeal fixation (MLF) with McGRATH® MAC (McGRGTH)
Number of subjects: 31
Study 27236886 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM clinical outcomes rating scale for HF (TCM‐HF‐PRO)
Number of subjects: 340
Study 27236886 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 340
Study 24411226 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 227
Study 22709810 — intervention group
Group type: EXPERIMENTAL
Intervention: High reduced-fat dairy, cereal, nuts, and fruits dietary pattern (rural)
Number of subjects: 729
Study 22709810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed dietary pattern (rural)
Number of subjects: 729
Study 22709810 — intervention group
Group type: EXPERIMENTAL
Intervention: High fruits and vegetables dietary pattern (urban)
Number of subjects: 729
Study 19238808 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine, 600 mg (n=12)
Number of subjects: 54
Study 19238808 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil, 400 mg (n=12)
Number of subjects: 54
Study 19238808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine, 20 mg (n=16)
Number of subjects: 54
Study 19238808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=14)
Number of subjects: 54
Study 17303771 — intervention group
Group type: EXPERIMENTAL
Intervention: Activate‐Initiate‐Monitor care management program
Number of subjects: 188
Study 17303771 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 188
Study 15351753 — intervention group
Group type: COMPARATOR
Intervention: Peer leader education
Number of subjects: 638
Study 15351753 — intervention group
Group type: COMPARATOR
Intervention: Planned care (nurse-mediated organizational change + peer leader education)
Number of subjects: 638
Study 11607890 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (Group 1)
Number of subjects: 24
Study 11607890 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol + vaginal progesterone (Group 2)
Number of subjects: 24
Study 11607890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestradiol + vaginal progesterone (Group 3)
Number of subjects: 24
Study 11607890 — intervention group
Group type: COMPARATOR
Intervention: Control group without therapy (Group 4)
Number of subjects: 24
Study 9675656 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 million units of natural human fibroblast beta interferon three times a week for 12 months
Number of subjects: 92
Study 9675656 — intervention group
Group type: COMPARATOR
Intervention: 3 million units of natural human fibroblast beta interferon three times a week for 12 months
Number of subjects: 92
Study 9675656 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 million units of natural human fibroblast beta interferon
Number of subjects: 92
Study 8032838 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization (CIC) weekly for 1 year
Number of subjects: 43
Study 8032838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CIC)
Number of subjects: 43
Study 1922166 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1 g/orally b.i.d.)
Number of subjects: 24
Study 1922166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6763836 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural treatment programme
Number of subjects: 0
Study 6763836 — intervention group
Group type: COMPARATOR
Intervention: Cardiological measures (e.g. diet, exercise, adherence to medication)
Number of subjects: 0
Study 31302644 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham opioid infusion (saline solution)
Number of subjects: 73
Study 31302644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo conditioning (increased experimental pain)
Number of subjects: 73
Study 31302644 — intervention group
Group type: COMPARATOR
Intervention: Natural history (control group)
Number of subjects: 73
Study 27550386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/exenatide
Number of subjects: 50
Study 27550386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25720388 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous exenatide for 11 days
Number of subjects: 68
Study 25720388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous exenatide
Number of subjects: 68
Study 25720388 — intervention group
Group type: COMPARATOR
Intervention: Exendin-9 (GLP-1R antagonist)
Number of subjects: 68
Study 25720388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (ex vivo on human subcutaneous adipose tissue arterioles)
Number of subjects: 68
Study 25720388 — intervention group
Group type: COMPARATOR
Intervention: AMPK inhibition
Number of subjects: 68
Study 24494281 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60
Study 24494281 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60
Study 21178639 — intervention group
Group type: EXPERIMENTAL
Intervention: LDCT arm
Number of subjects: 100
Study 21178639 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 100
Study 19809230 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial injection of 9 ml bupivacaine and 1 ml betamethasone
Number of subjects: 56
Study 19809230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 56
Study 17520986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil (2 microg/kg)
Number of subjects: 60
Study 17520986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg in cherry juice)
Number of subjects: 60
Study 17520986 — intervention group
Group type: COMPARATOR
Intervention: Oral tramadol (3 mg/kg drops)
Number of subjects: 60
Study 15567986 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine (20 microg doses at months 0, 1, and 6)
Number of subjects: 321
Study 12368393 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g FOS + 80 mg cornstarch
Number of subjects: 68
Study 12368393 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g sucrose + 1 x 10(9) cfu LAC
Number of subjects: 68
Study 12368393 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g FOS + 1 x 10(9) cfu LAC
Number of subjects: 68
Study 12368393 — intervention group
Group type: COMPARATOR
Intervention: 3 g sucrose + 80 mg cornstarch
Number of subjects: 68
Study 9700882 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocorrective therapy
Number of subjects: 57
Study 9700882 — intervention group
Group type: COMPARATOR
Intervention: Chronic bacterial prostatitis
Number of subjects: 57
Study 7985753 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria sporozoite vaccine (R32NS1(81))
Number of subjects: 12
Study 7985753 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 volunteers)
Number of subjects: 12
Study 3134815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolysis
Number of subjects: 109
Study 3134815 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 109
Study 30926654 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric cancer risk prediction rule (based on age, sex, PG I/II ratio, G-17 level, H. pylori infection, pickled food, fried food)
Number of subjects: 14929
Study 30926654 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroscopy for individuals with medium risk and high risk
Number of subjects: 14929
Study 30926654 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction rule
Number of subjects: 14929
Study 29292492 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt perforation of the ligamentum flavum (n=22)
Number of subjects: 50
Study 29292492 — intervention group
Group type: COMPARATOR
Intervention: Cutting of the ligamentum flavum (n=28)
Number of subjects: 50